JP2021523220A5 - - Google Patents
Info
- Publication number
- JP2021523220A5 JP2021523220A5 JP2021510264A JP2021510264A JP2021523220A5 JP 2021523220 A5 JP2021523220 A5 JP 2021523220A5 JP 2021510264 A JP2021510264 A JP 2021510264A JP 2021510264 A JP2021510264 A JP 2021510264A JP 2021523220 A5 JP2021523220 A5 JP 2021523220A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- formula
- composition
- mpn
- myelofibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024008582A JP2024050668A (ja) | 2018-04-30 | 2024-01-24 | がんの治療方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664673P | 2018-04-30 | 2018-04-30 | |
| US62/664,673 | 2018-04-30 | ||
| US201862701088P | 2018-07-20 | 2018-07-20 | |
| US62/701,088 | 2018-07-20 | ||
| US201862781942P | 2018-12-19 | 2018-12-19 | |
| US62/781,942 | 2018-12-19 | ||
| US201962834848P | 2019-04-16 | 2019-04-16 | |
| US62/834,848 | 2019-04-16 | ||
| PCT/US2019/029906 WO2019213074A1 (en) | 2018-04-30 | 2019-04-30 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024008582A Division JP2024050668A (ja) | 2018-04-30 | 2024-01-24 | がんの治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523220A JP2021523220A (ja) | 2021-09-02 |
| JP2021523220A5 true JP2021523220A5 (cg-RX-API-DMAC10.html) | 2022-05-09 |
Family
ID=68386769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510264A Pending JP2021523220A (ja) | 2018-04-30 | 2019-04-30 | がんの治療方法 |
| JP2024008582A Pending JP2024050668A (ja) | 2018-04-30 | 2024-01-24 | がんの治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024008582A Pending JP2024050668A (ja) | 2018-04-30 | 2024-01-24 | がんの治療方法 |
Country Status (20)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022004225A2 (pt) * | 2019-09-16 | 2022-05-31 | Novartis Ag | Uso de um inibidor de mdm2 para o tratamento de mielofibrose |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| WO2021175192A1 (en) * | 2020-03-02 | 2021-09-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment methods and biomarkers for mdm2 inhibitors |
| WO2022219128A1 (en) * | 2021-04-15 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | In vitro tests allowing to identify the potential for mdm2 inhibitors to induce the selection of mutations in patients suffering from a myeloproliferative neoplasm |
| EP4398903A4 (en) * | 2021-09-09 | 2025-07-16 | Kartos Therapeutics | METHODS FOR TREATING CANCER DEPENDENT ON MYC GENE EXPRESSION |
| EP4398905A4 (en) * | 2021-09-09 | 2025-07-16 | Kartos Therapeutics | METHODS OF TREATING CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| PT3456333T (pt) * | 2012-12-07 | 2020-06-01 | Geron Corp | Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica |
| WO2014134201A1 (en) * | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| MA53572A1 (fr) * | 2013-06-10 | 2021-10-29 | Amgen Inc | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
| MY192088A (en) | 2013-11-11 | 2022-07-26 | Amgen Inc | Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| KR102283895B1 (ko) * | 2013-12-23 | 2021-07-30 | 노파르티스 아게 | 제약 조합물 |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| TW201613576A (en) * | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
-
2019
- 2019-04-29 IL IL319432A patent/IL319432A/en unknown
- 2019-04-29 IL IL308399A patent/IL308399B2/en unknown
- 2019-04-30 SG SG11202010793UA patent/SG11202010793UA/en unknown
- 2019-04-30 JP JP2021510264A patent/JP2021523220A/ja active Pending
- 2019-04-30 CR CR20200576A patent/CR20200576A/es unknown
- 2019-04-30 US US17/052,040 patent/US12115153B2/en active Active
- 2019-04-30 CN CN202510038924.9A patent/CN120037232A/zh active Pending
- 2019-04-30 JO JOP/2020/0273A patent/JOP20200273A1/ar unknown
- 2019-04-30 TW TW108115047A patent/TWI741286B/zh active
- 2019-04-30 BR BR112020022148-1A patent/BR112020022148A2/pt unknown
- 2019-04-30 IL IL278345A patent/IL278345B2/en unknown
- 2019-04-30 WO PCT/US2019/029906 patent/WO2019213074A1/en not_active Ceased
- 2019-04-30 MX MX2020011608A patent/MX2020011608A/es unknown
- 2019-04-30 CN CN201980043405.4A patent/CN112512525A/zh active Pending
- 2019-04-30 KR KR1020257027602A patent/KR20250130704A/ko active Pending
- 2019-04-30 PE PE2020001785A patent/PE20211653A1/es unknown
- 2019-04-30 CA CA3098606A patent/CA3098606A1/en active Pending
- 2019-04-30 TW TW110132121A patent/TW202146387A/zh unknown
- 2019-04-30 AU AU2019263064A patent/AU2019263064B2/en active Active
- 2019-04-30 TN TNP/2020/000210A patent/TN2020000210A1/en unknown
- 2019-04-30 EP EP19796292.1A patent/EP3787625A4/en active Pending
- 2019-04-30 TW TW113138550A patent/TW202529759A/zh unknown
- 2019-04-30 KR KR1020207034245A patent/KR102849513B1/ko active Active
-
2020
- 2020-10-30 PH PH12020551820A patent/PH12020551820A1/en unknown
- 2020-10-30 MX MX2024003655A patent/MX2024003655A/es unknown
- 2020-10-30 CL CL2020002833A patent/CL2020002833A1/es unknown
- 2020-11-25 CO CONC2020/0014599A patent/CO2020014599A2/es unknown
-
2024
- 2024-01-24 JP JP2024008582A patent/JP2024050668A/ja active Pending
- 2024-09-26 US US18/898,634 patent/US20250090517A1/en active Pending
-
2025
- 2025-03-07 AU AU2025201686A patent/AU2025201686A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503365A5 (cg-RX-API-DMAC10.html) | ||
| IL278345B1 (en) | Methods of treating cancer | |
| JP2024507938A5 (cg-RX-API-DMAC10.html) | ||
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| RU2011134499A (ru) | Композиция 4-амино-2-(2,6-диоксопиперидин-3-ил)изоиндолин-1,3-диона | |
| JP2014526503A5 (cg-RX-API-DMAC10.html) | ||
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2023509968A5 (cg-RX-API-DMAC10.html) | ||
| JPH02240021A (ja) | 抑うつ障害の治療用に適した制御放出製薬組成物 | |
| JP2018090566A5 (cg-RX-API-DMAC10.html) | ||
| IL294582A (en) | Methods for treating an enlarged spleen | |
| JP2012521355A5 (cg-RX-API-DMAC10.html) | ||
| JP2023529365A5 (cg-RX-API-DMAC10.html) | ||
| RU2014129508A (ru) | Новая комбинация | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JP2023502941A5 (cg-RX-API-DMAC10.html) | ||
| JP2022512158A5 (cg-RX-API-DMAC10.html) | ||
| FI3713576T3 (fi) | Yhdiste kaavan (i) mukaan ja ponatinibi käytettäväksi bcr-abl-mutaatioiden kanssa esiintyvän kroonisen myelooisen leukemian hoidossa | |
| US20200289510A1 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing | |
| CN114945371A (zh) | 肥大细胞疾病和嗜酸性粒细胞疾病的治疗 | |
| JP2021530568A5 (cg-RX-API-DMAC10.html) | ||
| JP2021091608A5 (cg-RX-API-DMAC10.html) | ||
| JP2024506041A5 (cg-RX-API-DMAC10.html) | ||
| RU2020126340A (ru) | Способы и комбинированное терапевтическое средство для лечения рака |